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Previous studies suggest that the emerging
G9P[8] genotype was the most prevalent rota-
virus genotype in Ecuador during 2005. This
present study provides a temporal analysis of
the distribution of rotavirus genotypes in
two locations within Ecuador by adding addi-
tional years (2006 – early 2008) to the originally
reported 2005 data. Data were collected in a rural
(northern coastal Ecuador) and urban (Quito)
area. In the rural area, a community sample of
cases (those presenting diarrhea) and controls
(those not presenting diarrhea) were collected
between August 2003 and March 2008 resulting
in a total of 3,300 stool samples (876 cases and
2,424 controls). Of these samples, 260 were
positive for rotavirus by an immunochromato-
graphic test (196 cases and 64 controls). In Quito,
59 fecal samples were collected from children
presenting diarrhea and diagnosed with rotavi-
rus. An RT-PCR analysis of samples collected
between 2005 and 2007 suggested that G9 was
replaced by G1 and G2 in the rural and urban
settings. During this period G9 decreased from
79% to 9% while G2 increased from 0% to 43%
in the rural communities, and G9 decreased from
79% to 37% while G2 increased from 3% to 57% in
the urban area of Quito. This rapid replacement
of G9 by G1 and G2 reinforces the necessity of
surveillance to inform vaccination programs.
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INTRODUCTION
Rotavirus is an important cause of diarrhea respon-
sible for 454,000–705,000 childhood deaths each year
[Parashar et al., 2006]. This virus belongs to the
Reoviridae family. It has a three-layered capsid that
surrounds a genome made of 11 segments of double-
stranded RNA. The middle capsid layer is composed of
the VP6 protein, which is the most abundant protein and
permits classification into five groups (A through E)
based on the presence of specific epitopes. Most human-
infecting rotaviruses belong to group A [Estes and
Kapikian, 2007]. Proteins VP7 and VP4, also named G
and P respectively, comprise the outermost layer of the
capsid, and are used for typing purposes. The Rotavirus
Classification Working Group has catalogued 20 VP7
genotypes and 28 VP4 genotypes [Matthijnssens et al.,
2008; Solberg et al., 2009]. Globally, G1, G2, G3, G4, and
G9 are the most prevalent VP7 genotypes, whereas P[8],
P[4], and P[6] are the most prevalent VP4 genotypes
[Gentsch et al., 2005; Santos and Hoshino, 2005]. The
emerging G9 genotype has gained global importance
during the past 10 years [Santos et al., 2001, 2005; Clark
et al., 2004].
Rotavirus is diverse genotypically [Gentsch et al.,
2005]. This diversity presents challenges in developing
an effective vaccine. Available rotaviral vaccines have
been shown to confer protection against gastroenteritis
caused by genotypes homologous to those present in
their formulations [Ruiz-Palacios et al., 2006; Vesikari
et al., 2006], and a lower degree of protection against
genotypes not present in vaccines [Ruiz-Palacios et al.,
2006; Gurgel et al., 2007]. For example, these vaccine
formulations do not include the G9 antigen; and
although some vaccines have been shown to be protec-
tive for G9 genotypes, this may be largely due to the fact
that G9 has been generally associated with P8, an
antigen that is included in the vaccine formulations.
Two studies describing the rotavirus genotype dis-
tribution were conducted during 2005 in Ecuador
[Endara et al., 2007; Naranjo et al., 2008]. Both studies
showed that G9 was the most common genotype
circulating throughout the country (10 provinces within
the coastal, Andian, and Amazonian regions). The aim of
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this study is to present a temporal analysis of the
distribution of the rotavirus genotypes circulating in
22 rural communities in the northern coast and in a
children’s hospital in Quito between 2005 and 2007.
METHODS
Between August 2003 and March 2008, 22 rural
communities located in the northern coast of Ecuador
were visited seven times in a rotational sequence. Each
visit lasted for 15 days. Cases were defined as individ-
uals with three or more loose stools within a 24 hr period
and controls as individuals with no diarrhea within the
past 6 days. Through a daily active surveillance of all
households within a community, all cases of diarrhea
were identified. For each case of diarrhea, three addi-
tional control stool specimens were randomly collected,
one from within the case household and two from within
the case community. Fecal samples obtained from the
Hospital de Niños Baca Ortiz in Quito, from children
presenting diarrhea and diagnosed with rotavirus, were
collected between January 2007 and May 2007 to
complement the 2005 samples previously collected
[Endara et al., 2007]. A subset of the rural samples
(from February 2005 to December 2007) and a random
sample of 59 children (29 from 2005 and 30 from 2007)
from the Quito hospital were genotyped using RT-PCR.
All protocols were approved by the IRB committees of
the University of Michigan and Universidad San
Francisco de Quito.
Rotavirus Detection
All samples (symptomatic and non-symptomatic)
were analyzed for the presence of rotavirus with a
commercial immunochromatographic test (RIDA Quick
Rotavirus, R-Biopharm AG).
Rotavirus Multiplex RT-PCR
The rotavirus-positive samples were preserved in
liquid nitrogen and transported to Quito for PCR
genotyping. The double-stranded rotavirus RNA was
extracted from the stool specimens using TRIZOL
Reagent (Invitrogen Corp., Carlsbad, CA) or the Ultra-
Clean Tissue RNA Kit (MoBio Laboratories, Inc.,
Carlsbad, CA) according to protocols supplied by the
manufacturers. RNA was stored at 808C until further
use. A two-step, semi-nested multiplex RT-PCR was
carried out for G- and P-genotyping. Briefly, primers
9con1 and 9con2 were used for the first amplification of
the VP7 gene and primers 9T-1, 9T-2, 9T-3P, 9T-4, and
9T-9B were then used to ascertain the G genotype [Das
et al., 1994]. Primers Con3 and Con2 were used for the
partial amplification of the VP4 gene and primers 1T-1,
2T-1, 3T-1, 4T-1, 5T-1, and ND2 were then used to
ascertain the P genotype [Gentsch et al., 1992].
Viral RNA was denatured for 5 min at 978C. Retro-
transcription and the first amplification were carried
out using a SuperScript III RT/Platinum Taq polymer-
ase kit (Invitrogen Corp.). Primers were used at 200 nM
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each, and the 1X buffer provided by the manufacturer
contained 1.6 mM MgSO4 and 200mM of dNTPs. The
retrotranscription was carried out at 428C for 45 min
and stopped at 968C for 2 min. The first amplification
consisted of 30 cycles at 948C for 30 sec, 508C for 30 sec,
and 728C for 60 sec. The second amplification was
carried out using PuReTaq Ready-To-GoTM PCR beads
(Amersham Biosciences, Valley Stream, NY) and pri-
mers at a final concentration of 400 nM. The cycling
parameters were 30 cycles at 948C for 30 sec, 428C for
30 sec and 728C for 60 sec, and a final extension at 728C
for 1 min. Electrophoresis of the PCR product was run
with 1.8% agarose gels at 60 V and visualized under UV
light.
RESULTS
Between August 2003 and March 2008, a total of 3,300
stool samples were collected in 22 rural communities in
the northern coast of Ecuador (876 cases and 2,424
controls). Of these, 260 were positive by the commercial
immunochromatographic test (196 cases and 64 con-
trols). The presence of diarrhea was significantly
associated with rotavirus infection (odds ratio¼10.6;
95% CI: 7.9–14.3) (Table I), consistent with that
reported for the 2005 samples (odds ratio¼9.2; 95%
CI: 6.1–13.9) [Endara et al., 2007].
Of the 5 genotypes identified from the isolates, G9
represent 41% (90 of 220) while G1 and G2 represent
31% (68 of 220) of the samples (Table II). G1 and G2 had
similar trends over time in contrast with the G9
genotype, which had an opposing trend. These trends
were similar in both the rural communities of Esmer-
aldas as well as in the urban setting of Quito (Fig. 1).
While G9 was dominant strain during the calendar year
2005 (present in 79% of the isolates in both Esmeraldas
and Quito), it dropped within Esmeraldas to 28% and 9%
during 2006 and 2007 respectively, and within Quito to
37% during 2007. The genotypes G1 and G2, on the other
hand, was not identified in Esmeraldas during the
calendar year 2005 but was present in 43% of the isolates
in 2007. Similarly, in Quito, G2 was only isolated in 3%
of the samples in 2005 but in 57% of the samples in 2007.
Ten percent of the samples had no detectable VP7
gene, which determines the G genotype, but did have a
detectable VP4 gene providing an identification of the P
genotype. Thirteen percent of the samples had no
detectable VP4 or VP7 gene resulting in an untypeable
classification. All but one of these untypeable isolates
were from the Esmeraldas samples (Table II).
DISCUSSION
In a previous publication, data was presented showing
that in 2005 G9 was the dominant strain circulating
along the coast of Esmeraldas and in the Andean city of
Quito [Endara et al., 2007]. This was consistent with
another study describing rotavirus in urban settings in
Ecuador [Naranjo et al., 2008]. There have been many
other studies corroborating the emergence of G9
rotavirus in Latin America [Gentsch et al., 2005; Santos
and Hoshino, 2005]. The genotypes G1 and G2, on the
other hand, were not found in the 22 rural communities
and were minor genotypes in samples from the urban
hospital. The follow-up study presented here suggests
that within 2 years, G9 was replaced by G1 and G2 in
these same two regions of Ecuador. This increase in the
G2 genotype is consistent with that observed in Brazil,
El Salvador, Guatemala, Honduras, Argentina, and
Paraguay [Leite et al., 2008].
Other studies have also shown that the prevalent
rotavirus genotypes circulating within a population can
change in short periods of time. In Thailand, during
the years 2000–2001, the most prevalent genotype was
G9; by the year 2003, G2 emerged as the prevailing
genotype but only to decline again in 2004, when G1
became the most common genotype [Khamrin et al.,
2007]. In Bangladesh between 2001 and 2005, the
J. Med. Virol. DOI 10.1002/jmv
TABLE II. Distribution of G and P Types of Rotavirus by Year in Rural Communities of Esmeraldas and in Quito Ecuador
by Yeara
Genotype
Number of strains detected
Total
Esmeraldas Quito
2005 2006 2007 2005 2007
G1 (P[6], PNT) 3 17 1 1 0 22
G2 (P[4], P[8], P[9], PNT) 0 9 19 1 17 46
G3 P[6] 0 1 0 0 0 1
G4 P[6] 0 4 0 0 2 6
G9 (P[4], P[6], P[8], PNT) 34 19 4 23 10 90
GNT (P[4], P[8], P[9]) 2 9 11 0 0 22
G4/G9 P[6] 0 0 0 0 1 1
G2/G9 (P[8], P[4]) 0 0 0 3 0 3
PNT GNT 7 9 12 1 0 29
Total 46 68 47 29 30 220
aAs determined by genotype specific, multiplex reverse transcription-PCR. Samples were collected from 21 rural communities in Borbón
Esmeraldas and from Quito, February 2005–December 2007. Undetermined types are designated NT. Coinfection with different genotypes is
designated with a slash.
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prevailing strains belonged to genotypes G1P[8] and
G9P[8], however, in the 2005–2006 season G2P[4]
became predominant [Rahman et al., 2005].
Changes in genotypic patterns within a population
may be explained by the interplay between the popula-
tion’s immunity and viral evolution. The presence of
antibodies against a given rotavirus serotype can
prevent re-infections by the antigenically related
viruses but not against other distinct serotypes [Franco
et al., 2006]. Additionally, new highly infective viral
strains may emerge only to disappear when populations
reach herd immunity [Kobasa et al., 2004].
Some samples from the rural communities could not
be genotyped. A previous study provided evidence that
these isolates may be novel strains [Solberg et al., 2009].
This would suggest that the G9 strain was able to
temporarily supplant these indigenous novel strains,
explaining the higher proportion of isolates that could be
typed during 2005 (Fig. 1A). The presence of unusual
strains often occur in developing countries and are likely
to occur due to human contact with animals [Gentsch
et al., 2005; Franco et al., 2006]. These zoonotic
infections can promote the emergence of new genotypes
by viral reassortment.
In Ecuador two vaccines, the monovalent (Rotarix1)
and pentavalent (Rotateq1) vaccines, are approved and
are being used in vaccination campaigns. This sudden
change in rotavirus genotypes prevalence over time
reinforces the need for rotaviral surveillance studies
while vaccination programs are ongoing.
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Fig. 1. Percent isolates identified as genotype G1 or G2, G9 by year (white: 2005, gray: 2006, black: 2007)
from (A) Esmeraldas; (B) Quito. NT designates undetermined types for both G and P. ‘‘Other’’ includes
genotypes G3, G4, or GNT associated with a specific P type.
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